Related references
Note: Only part of the references are listed.Updated Insights on EGFR Signaling Pathways in Glioma
Alexandru Oprita et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Mobocertinib: First Approval
Anthony Markham
DRUGS (2021)
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma
Joseph S. Durgin et al.
FRONTIERS IN ONCOLOGY (2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Naoko Okura et al.
CLINICAL CANCER RESEARCH (2020)
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
Dima A. Sabbah et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
Neratinib: the emergence of a new player in the management of HER2+breast cancer brain metastasis
Azadeh Nasrazadani et al.
FUTURE ONCOLOGY (2020)
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James C. H. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
Tania Crombet Ramos et al.
FRONTIERS IN ONCOLOGY (2020)
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Wen-Qi Cai et al.
FRONTIERS IN ONCOLOGY (2020)
Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with miR-634 Ointment
Jun Inoue et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma
Puey Ling Chia et al.
EXPERT OPINION ON DRUG DELIVERY (2019)
Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies
Sarah Ahn et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
Sally C. M. Lau et al.
DRUGS (2019)
Current Approaches in NSCLC Targeting K-RAS and EGFR
Veronica Aran et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Amaia Eleonora Maennling et al.
CANCERS (2019)
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
Yan Liu et al.
AGING-US (2019)
Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer
T. Nagano et al.
DRUGS OF TODAY (2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
Andrew G. Hill et al.
CLINICAL CANCER RESEARCH (2018)
Cetuximab for treating non-small cell lung cancer
Luca Mazzarella et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3
Hester A. Doyle et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Trial watch: Peptide-based vaccines in anticancer therapy
Lucillia Bezu et al.
ONCOIMMUNOLOGY (2018)
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Regulation of EGFR Endocytosis by CBL During Mitosis
Ping Wee et al.
CELLS (2018)
Population Pharmacokinetics of Necitumumab in Cancer Patients
Amanda Long et al.
CLINICAL PHARMACOKINETICS (2017)
Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer
Antonio Rossi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
Yuji Miyamoto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway
Un-Jung Yun et al.
CELL DEATH & DISEASE (2017)
EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo
Itziar Pinilla-Macua et al.
ELIFE (2017)
Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
Greta Garrido et al.
FRONTIERS IN PHARMACOLOGY (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Current Landscape of Targeted Therapy in Lung Cancer
Manasi K. Mayekar et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
EGFR-targeted therapies in the post-genomic era
Mary Jue Xu et al.
CANCER AND METASTASIS REVIEWS (2017)
EGFR inhibition in NSCLC: New findings.... and opened questions?
Francesco Passiglia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies
Jonathan Moreira et al.
DRUGS (2017)
Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance
Sally Temraz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
The endosomal transcriptional regulator RNF11 integrates degradation and transport of EGFR
Sandra Scharaw et al.
JOURNAL OF CELL BIOLOGY (2016)
MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer
Sara Donzelli et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Valerio Gelfo et al.
ONCOTARGET (2016)
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Nathan Simon et al.
TOXINS (2016)
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Jerome Fayette et al.
FRONTIERS IN ONCOLOGY (2016)
EGF stimulates the activation of EGF receptors and the selective activation of major signaling pathways during mitosis
Ping Wee et al.
CELLULAR SIGNALLING (2015)
Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis
Camilo Garay et al.
MOLECULAR BIOLOGY OF THE CELL (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer
Fei Han et al.
BIOMED RESEARCH INTERNATIONAL (2015)
MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression
Merav Kedmi et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
Emily Padfield et al.
FRONTIERS IN ONCOLOGY (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions
Solange Peters et al.
CANCER TREATMENT REVIEWS (2014)
Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases
Fengfeng Wang et al.
GENOMICS (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
Mohammad Hojjat-Farsangi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
Bing Li et al.
LUNG CANCER (2014)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
EGF receptor trafficking: consequences for signaling and cancer
Alejandra Tomas et al.
TRENDS IN CELL BIOLOGY (2014)
Targeting EGFR and PI3K pathways in ovarian cancer
S. Glaysher et al.
BRITISH JOURNAL OF CANCER (2013)
Spatial Regulation of Epidermal Growth Factor Receptor Signaling by Endocytosis
Brian P. Ceresa
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
Fares Al-Ejeh et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Helena A. Yu et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma
B. Kalman et al.
NEUROMOLECULAR MEDICINE (2013)
SPIN90 Knockdown Attenuates the Formation and Movement of Endosomal Vesicles in the Early Stages of Epidermal Growth Factor Receptor Endocytosis
Hyejin Oh et al.
PLOS ONE (2013)
Sustained Activation of Protein Kinase C Induces Delayed Phosphorylation and Regulates the Fate of Epidermal Growth Factor Receptor
Mengling Liu et al.
PLOS ONE (2013)
Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
Jennifer Wheler et al.
ONCOTARGET (2013)
Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
Mari Iida et al.
NEOPLASIA (2013)
Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis
Christian Berger et al.
EXPERIMENTAL CELL RESEARCH (2012)
Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
Ana Markovic et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor
Lingxiang Liu et al.
FEBS JOURNAL (2012)
Endosomal Accumulation of the Activated Epidermal Growth Factor Receptor (EGFR) Induces Apoptosis
Jamie S. Rush et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Lapatinib for Advanced or Metastatic Breast Cancer
Frans L. Opdam et al.
ONCOLOGIST (2012)
Differential Roles of Grb2 and AP-2 in p38 MAPK- and EGF-Induced EGFR Internalization
Michael V. Grandal et al.
TRAFFIC (2012)
JAK2 the future: therapeutic strategies for JAK-dependent malignancies
Lindsay M. LaFave et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Toni M. Brand et al.
CANCER BIOLOGY & THERAPY (2011)
ERBB2 is a target for USP8-mediated deubiquitination
Inez M. J. Meijer et al.
CELLULAR SIGNALLING (2011)
Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
Fausto Petrelli et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2011)
MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1
William C. S. Cho et al.
RNA BIOLOGY (2011)
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Takeshi Yoshida et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme Clinical article
Linna Li et al.
JOURNAL OF NEUROSURGERY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
VAV2 regulates epidermal growth factor receptor endocytosis and degradation
S. Thalappilly et al.
ONCOGENE (2010)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E. Martinelli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Melarkode S. Ramakrishnan et al.
MABS (2009)
EGFR-targeted therapies in lung cancer: predictors of response and toxicity
Rebecca Suk Heist et al.
PHARMACOGENOMICS (2009)
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
G. J. Weiss et al.
ANNALS OF ONCOLOGY (2008)
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
Kirstine Roepstorff et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Targeting epidermal growth factor receptor and Src pathways in head and neck cancer
Ann Marie Egloff et al.
SEMINARS IN ONCOLOGY (2008)
Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer
Andres Upez-Albaitero et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2007)
Mechanisms for oncogenic activation of the epidermal growth factor
Roza Zandi et al.
CELLULAR SIGNALLING (2007)
Regulation of MAPKs by growth factors and receptor tyrosine kinases
Menachem Katz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
The JNK signal transduction pathway
Claire R. Weston et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies
AB Riemer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
A comprehensive pathway map of epidermal growth factor receptor signaling
Kanae Oda et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
An epidermal growth factor receptor chimeric human-murine monoclonal antibody
J Harding et al.
DRUGS OF TODAY (2005)
c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes
T Ravid et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway
Dawn R. Mattoon et al.
BMC BIOLOGY (2004)
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
CM Silva
ONCOGENE (2004)
An integrated model of epidermal growth factor receptor trafficking and signal transduction
H Resat et al.
BIOPHYSICAL JOURNAL (2003)
Escape from Cbl-mediated downregulation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases
P Peschard et al.
CANCER CELL (2003)
The ErbB receptors and their role in cancer progression
T Holbro et al.
EXPERIMENTAL CELL RESEARCH (2003)
Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac
P Tamás et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways
JA Witowsky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Coordinated traffic of Grb2 and Ras during epidermal growth factor receptor endocytosis visualized in living cells
XJ Jiang et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Identification of CDK4 as a target of c-MYC
H Hermeking et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
